The acquisition aligns with Granules' vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market
Biocon Biologics remains committed to global standards of quality and compliance
The inspection scope had included six separate Biologics manufacturing units comprising of four Drug Substance and two Drug Product manufacturing plants
The US District Court of New Jersey decided to grant a preliminary injunction delaying the launch of LEQSELVI
The inspection concluded with the issuance of a form 483 with five observations
The inspection scope included 6 separate Biologics manufacturing units comprising 4 Drug Substance and 2 Drug Product manufacturing plants
Zydus receives final approval from USFDA for its NDA Zituvimeta, extended-release tablets
The inspection was a cGMP Inspection and had ended with NIL observations
Cipla has received 8 inspectional observations in Form 483
Subscribe To Our Newsletter & Stay Updated
